Ionis rides 2026 FDA approvals as analysts cut price targets
Ionis Pharmaceuticals says 2026 FDA approvals and launch momentum will drive growth, while analysts trimmed price targets cited as Morgan Stanley, Barclays, Goldman Sachs, BMO and Canaccord.